The Genentech Indirect Access Program manages access to products, for facilities that wish to purchase any of our Limited Distribution Products indirectly from a wholesaler or specialty distributor.
If the facility meets access eligibility, the facility will receive an indirect access agreement, or certification, allowing them to purchase that product from an authorized wholesaler or specialty distributor.
Click below for details on access eligibility and what happens after a request is evaluated:
If your facility/pharmacy is approved for an indirect access, via Letter of Agreement (LOA) or Restricted Access Certification (RAC)
After executing an LOA our Data Reporting team will reach out with an orientation on the different sales reporting mechanisms and how to manage the data reporting requirements of your agreement.
Data Reporting can be fulfilled in one of two ways:
Once approved, and if the Contract Operations team receives a timely return of the signed LOA, the process to gain pharmacy or infusion site product access can be as soon as 4-5 business days. Lapses in communication or incomplete submissions can add unforeseeable time to the execution of an indirect access LOA.
In some cases, we are unable to extend indirect access to a facility for a number of reasons, including but not exclusively when the existing distribution network is considered sufficient for meeting patient access. If your request is denied, you may pursue a Patient Specific exception or learn other options by contacting Genentech Access Solutions.
A Patient Specific Exception may be approved if one of the criteria below apply:
If your facility is not eligible for indirect access and any of the above apply please contact our Access Solutions team at (866) 422‑2377 regarding Patient Specific Exception eligibility.